Biogen (BIIB) 6% Lower as Aducanumab Timeline Pushed Out

April 22, 2020 7:50 AM EDT Send to a Friend

Biogen (NASDAQ: BIIB) is down 6% in pre-open ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Biogen (BIIB) 6% Lower as Aducanumab Timeline Pushed Out

Member Login

Free News Feed